STOCK TITAN

Iveric Bio to Report Third Quarter 2021 Financial Results and Host Conference Call on Tuesday, November 9, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Iveric Bio (NASDAQ: ISEE) will release its third quarter 2021 financial results on November 9, 2021, at 8:00 a.m. ET. A conference call will follow to discuss these results and provide a business update. Interested participants can join by calling 1-888-317-6003 (USA) or 1-412-317-6061 (International), using passcode 0259351. The call will be available via audio webcast on the Iveric Bio website. The company is focused on developing treatments for retinal diseases, including age-related macular degeneration.

Positive
  • Scheduled earnings announcement may indicate a commitment to transparency and regular updates for investors.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 0259351. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 1-877-344-7529 (USA Toll Free), passcode 10161071.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release. Iveric Bio anticipates that subsequent events and developments will cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

ISEE-G

Investor Contact:

Iveric Bio

Kathy Galante, 212-845-8231

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com



or



Media Contact:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

Source: IVERIC bio, Inc.

FAQ

When will Iveric Bio report its Q3 2021 earnings?

Iveric Bio will report its Q3 2021 earnings on November 9, 2021.

What time is the Iveric Bio conference call for Q3 earnings?

The conference call for Iveric Bio's Q3 earnings will be held at 8:00 a.m. ET.

How can I access the Iveric Bio earnings call?

You can access the Iveric Bio earnings call by dialing 1-888-317-6003 (USA) or 1-412-317-6061 (International), using passcode 0259351.

What is the main focus of Iveric Bio's business?

Iveric Bio is focused on developing treatments for retinal diseases, particularly age-related macular degeneration.

ISEE

NASDAQ:ISEE

ISEE Rankings

ISEE Latest News

ISEE Stock Data

5.51B
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York